2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 2: February 28, 2024 - WCM24 Your Questions Answered
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, February 28, 2024
8 PM ET / 5 PM PT
Winter Clinical Dermatology Conference-Miami (WCM24): Your Questions Answered
This activity is supported by educational grants from Genentech, a member of the Roche Group, Novartis Pharmaceuticals Corporation, and Sanofi and Regeneron Pharmaceuticals.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
February 29, 2024
March 29, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss current management advancement in dermatology from rashes through tumors
Compare strategies to manage dermatologic conditions from laser treatment through systemic therapies
Identify appropriate treatment options for dermatologic conditions based on patient and disease characteristics
Recognize the nuances of managing dermatologic conditions in skin of color
Underline strategies to optimize management in patients with dermatologic conditions
Illustrate strategies to manage dermatologic conditions effectively in clinical practice
Intended Audience
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
James Del Rosso, DO
Adjunct Clinical Professor, Dermatology
Touro University Nevada
Henderson, NV
Gary Goldenberg, MD
Assistant Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Mark Nestor, MD, PhD
Director of Center for Clinical and Cosmetic Research
Voluntary Professor, Dermatology
University of Miami, Miller School of Medicine
Miami, FL
Darrell Rigel, MD, MS
Clinical Professor of Dermatology
New York University
Grossman School of Medicine
New York, NY
Adjunct Professor
UT Southwestern Medical School
Consultant Dermatologist, Cooper Clinic
Dallas, TX
Linda Stein Gold, MD
Director Clinical Research
Henry Ford Health System
Detroit, MI
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel
Grant/Research Support: Aclaris, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch (Ortho), Biorasi, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermavant, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO, Lilly, Novan, Pfizer, Ralexar, Sanofi Genzyme Regeneron, Sol-Gel, SUN, Vyne
Consultant: Abbvie, Aclaris, Almirall, Amgen, Arcuits, Bausch (Ortho), Biofrontera, Biopharmx, Blue Creek, BMS, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Evoummune, Ferndale, Galderma, Incyte, Jem Health, LEO, La Roche Posay, Lilly, MC2, Novan, Pfizer, Sanofi Genzyme Regeneron, Sente, Sol-Gel, Sonoma, SUN, UCB, Verrica, Vyne
Speakers’ Bureau or Honoraria: Abbvie, Aclaris, Almiral, Amgen, Bausch (Ortho), Biofrontera, Encore, EPI Health Ferndale, Galderma, Genentech, Jem Health, LEO, Lilly, Pfizer, Sanofi Genzyme Regeneron, SUN, UCB, Verrica, Vyne
Grant/Research Support: Biofrontera
Consultant: CoolHealth, Cutera, Galderma, Regeneron, Sanofi, Scibase
Speakers’ Bureau or Honoraria: Regeneron Sanofi
Ownership Interest: Verrica
Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.
Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.
Grant/Research Support: CROMA Pharma, Galderma, Merz
Consultant: CROMA Pharma, Revian, Sensus
Speakers’ Bureau or Honoraria: Allergan, AMP, Galderma, Hugel, Sensus
Grant/Research Support: Castle Biosciences, SciBASE
Consultant: DermTech, Ferndale Laboratories, Inc., SciBase, VYNE Therapeutics
Speakers’ Bureau or Honoraria: Castle Biosciences
Advisory Board: Almirall, Beiersdorf, Inc., Castle Biosciences, Johnson and Johnson
Grant/Research Support: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Consultant: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Speakers’ Bureau or Honoraria: Leo, AbbVie, Almirall, Galderma, Pfizer, Sanofi, Regeneron
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.